A Recombinant Humanized Monoclonal Antibody for Treatment of Endometriosis in a Rat Model

Abstract

Aim Angiogenesis plays an important role in the pathogenesis of endometriosis. Thus, the inhibition of angiogenesis may prevent endometriosis. Bevacizumab is a recombinant humanized monoclonal antibody against VEGF. The aim of this study is to investigate the efficacy of anti-VEGF therapy on the prophylaxis and treatment of endometriotic foci in a rat model. Methods This experimental study is prospective, randomized, and placebo-controlled. Thirty-six Wistar-Albino female rats were divided into 3 groups. Experimental endometriosis was induced by the implantation of autologous endometrial tissue. The bevacizumab administration route was intraperitoneal. Group A was the prophylaxis group; Group B was the treatment group, and Group C was the control group. The volumes of the implants as well as their VEGF and Ki-67 immunohistochemical staining are main outcome measures. Results The volumes of the lesions were smaller in Group A than Group C [P<.05]. The volumes of endometriotic foci in Group B were smaller than in Group C [P<.05]. Bevacizumab caused regression and atrophy of the endometriotic lesions. After the treatment the histopathologic and immunohistochemical scores in Group B were less than before treatment and less than the scores in Group C. Conclusions Bevacizumab treatment had a regressive effect on the endometriotic implants. As an anti-VEGF agent, bevacizumab has beneficial effects on the prophylaxis and treatment of endometriosis.